a public good project by the
Synthesis
Company
of California

© 2026

Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies | doi.page

0 citations0 references

Google Scholar doi.org

Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies

Nature Medicine·2013·Vol. 19(8), pp. 998–1004

Citations Over TimeTop 1% of 2013 papers

Andrew S. Lee, Chad Tang, Mahendra S. Rao, Irving L. Weissman, Joseph C. Wu

Related Papers

→ Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies(2017)92 cited
→ The reprogramming therapy for a patient with advanced hepatocellular carcinoma by using human-induced pluripotent stem (iPS) cells technology(2013)3 cited
The research advances on human induced pluripotent stem cells in vitro to produce red blood cells(2015)
Abstract 20894: Therapeutic Efficacy of the Exosomes Derived From Human Induced Pluripotent Stem Cells (iPSCs) vs. Human Induced Pluripotent Stem Cells-Derived Cardiomyocytes (iCMs) in Murine Myocardial Injury Model(2017)
→ Modeling Hypertrophic Cardiomyopathy with Human Induced Pluripotent Stem Cells(2016)